Cambridge Laboratories launches neuromotor drug in Italy

Xenazina (tetrabenazine), a dopamine depleting agent, was exclusively licensed by Cambridge to Chiesi in 2003 for commercialisation in Italy. The approval of Xenazina in Italy follows on from the recent successful launches of the product in Germany and France and continues Cambridge’s focus in specialist secondary care.

Xenazina has been approved for the treatment of movement disorders associated with Huntington’s disease and for the treatment of moderate to severe tardive dyskinesia, both conditions for which there is major unmet medical need.

Cambridge has worldwide rights to tetrabenazine and markets the product through its own direct sales force in the UK and Eire, and through marketing partners in Europe and other global markets. Xenazina will be marketed in Italy by a specialist team of 22 sales consultants.

Mark Evans, CEO of Cambridge, said: “We are delighted to see the launch of Xenazina in Italy which continues the successful roll-out of Xenazine in the major European territories. We are very excited about the opportunities within the European CNS market and the commercialisation of Xenazina further strengthens Cambridge’s position within this important field.”